Patents Assigned to Bayer Pharma AG
-
Patent number: 11617751Abstract: The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.Type: GrantFiled: December 20, 2012Date of Patent: April 4, 2023Assignee: BAYER PHARMA AGInventor: Kristina King
-
Patent number: 10059707Abstract: The present invention relates to a novel and improved process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I) and also the preparation and use of the crystalline polymorph I of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (I).Type: GrantFiled: July 29, 2015Date of Patent: August 28, 2018Assignee: BAYER PHARMA AGInventors: Johannes Platzek, Gunnar Garke, Alfons Grunenberg
-
Publication number: 20180235961Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).Type: ApplicationFiled: August 12, 2016Publication date: August 23, 2018Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma AGInventors: Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack
-
Patent number: 9126998Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: March 7, 2013Date of Patent: September 8, 2015Assignee: BAYER PHARMA AGInventors: Alexandros Vakalopoulos, Markus Follmann, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haβfeld, Niels Lindner, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva-Maria Becker, Andreas Knorr
-
Publication number: 20150174142Abstract: The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive.Type: ApplicationFiled: March 9, 2015Publication date: June 25, 2015Applicant: BAYER PHARMA AGInventor: Andreas SACHSE
-
Patent number: 8658788Abstract: This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbolactones of formula II as well as 3-oxo-pregn-4-ene-21,17-carbolactones of formula III by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes of formula I In addition, the invention relates to the dichloromethane hemisolvate of 6?,7?;15?,16?-dimethylene-3-oxo-17?-pregnan-5?-ol-21,17-carbolactone (IV) as such as well as to a process for the production of drospirenone.Type: GrantFiled: July 21, 2011Date of Patent: February 25, 2014Assignee: Bayer Pharma AGInventors: Carsten Seilz, Hartmut Seba
-
Patent number: 8597568Abstract: The present invention provides a method for inactivating viruses and/or bacteria in medicinal-leech extracts by means of electromagnetic radiation.Type: GrantFiled: October 8, 2010Date of Patent: December 3, 2013Assignee: Bayer Pharma AGInventors: Sebastian Schmidt, Jörg Peters, Juergen Michels
-
Patent number: 8557776Abstract: The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.Type: GrantFiled: September 7, 2007Date of Patent: October 15, 2013Assignee: Bayer Pharma AGInventors: Lutz Lehmann, Ananth Srinivasan, Thomas Brumby, Detlef Suelzle, Timo Stellfeld, Keith Graham, Mylene Tania Karramkam, Simon Ametamey
-
Patent number: 8551074Abstract: Systems for connecting a conduit to an injection needle may include a sealing element positioned on a distal end of the conduit, a first cooperating connector positioned around the length of conduit proximal to the sealing element and a second cooperating connector. The first cooperating connector includes a first cooperating connection mechanism and the second cooperating connector includes a second cooperating connection mechanism having a passage therein. The first cooperating connection mechanism and the second cooperating connection mechanism are adapted to form a connection between the first cooperating connector and the second cooperating connector. The connection causes the compression of the sealing element. The injection needle has a lumen with a diameter flared outward to a larger diameter at a proximal end.Type: GrantFiled: September 8, 2008Date of Patent: October 8, 2013Assignee: Bayer Pharma AGInventors: Raymond C. Hoffman, Edward J. Rhinehart, Kevin P. Cowan, Barry L. Tucker
-
Publication number: 20130226113Abstract: The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV-radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.Type: ApplicationFiled: March 15, 2013Publication date: August 29, 2013Applicant: Bayer Pharma AGInventor: Bayer Pharma AG
-
Patent number: 8501720Abstract: A method of treatment of dysmenorrhea in the context of oral contraception characterized by daily administration of ethinylestradiol and drospirenone in an extended regimen.Type: GrantFiled: August 1, 2005Date of Patent: August 6, 2013Assignee: Bayer Pharma AGInventors: Renate Heithecker, Bernd Duesterberg
-
Publication number: 20130178452Abstract: The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.Type: ApplicationFiled: December 20, 2012Publication date: July 11, 2013Applicant: BAYER PHARMA AGInventor: Bayer Pharma AG
-
Publication number: 20130165421Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).Type: ApplicationFiled: November 30, 2012Publication date: June 27, 2013Applicant: BAYER PHARMA AGInventor: Bayer Pharma AG
-
Publication number: 20130144062Abstract: The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.Type: ApplicationFiled: July 9, 2012Publication date: June 6, 2013Applicant: Bayer Pharma AGInventors: Martin Hendrix, Frank-Gerhard Böß, Christina Erb, Joachim Krüger, Joachim Luithle, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese
-
Patent number: 8439868Abstract: The present disclosure relates to balloon catheter medical devices. Some balloon catheter medical devices may include a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried. The dried paclitaxel may be immediately releasable after coming into contact with tissue. Other balloon catheter medical devices may include a balloon surface having a lipophilic proliferation inhibitor, an inflammation inhibitor, or an antioxidant adhered thereto.Type: GrantFiled: May 19, 2010Date of Patent: May 14, 2013Assignee: Bayer Pharma AGInventors: Ulrich Speck, Bruno Scheller
-
Publication number: 20130089574Abstract: The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.Type: ApplicationFiled: May 29, 2012Publication date: April 11, 2013Applicant: Bayer Pharma AGInventors: Karin SCHMIDT-GOLLWITZER, Gunter STOCK
-
Patent number: 8399627Abstract: Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF?); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.Type: GrantFiled: December 24, 2008Date of Patent: March 19, 2013Assignee: Bayer Pharma AGInventors: Christian Votsmeier, Uwe Gritzan, Kornelia Kirchner, Michael Strerath, Kerstin Baral, Ulrich Haupts, Wayne M. Coco, Susanne Steinig, Andreas Scheidig, Klaus Pellengahr, Simone Brückner, Hanna Plittersdorf, Peter Scholz, Jan Tebbe
-
Patent number: 8394958Abstract: The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.Type: GrantFiled: November 21, 2008Date of Patent: March 12, 2013Assignee: Bayer Pharma AGInventors: Markus Berger, Hartmut Rehwinkel, Thomas Zollner, Ekkehard May, Jorma Hassfeld, Heike Schacke
-
Publication number: 20130005766Abstract: The present invention relates to compounds of formula I, processes for their production and their use as anti-inflammatory agents.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Applicant: BAYER PHARMA AGInventors: Markus BERGER, Hartmut REHWINKEL, Thomas ZOLLNER, Bkkehard MAY, Jorma HASSFELD, Heike SCHACKE
-
Patent number: 8343745Abstract: The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.Type: GrantFiled: August 31, 2010Date of Patent: January 1, 2013Assignee: Bayer Pharma AGInventors: Stefan Golz, Ulf Brüggemeier, Bernhard Weingartner, Andreas Geerts